Italia markets close in 50 minutes
FTSE MIB
32.828,86 +163,65 (+0,50%) Dow Jones
38.511,28 -77,88 (-0,20%) Nasdaq
17.699,45 +10,57 (+0,06%) Nikkei 225
38.102,44 -712,12 (-1,83%) Petrolio
79,42 +0,97 (+1,24%) Bitcoin EUR
61.277,03 -819,82 (-1,32%)
NBIX Sep 2024 175.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 02:55PM EDT. Mercato aperto.
| Chiusura precedente | 3,2000 |
| Aperto | 3,2000 |
| Denaro | 0,1500 |
| Domanda | 4,8000 |
| Prezzo d'esercizio | 175,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 3,2000 - 3,2000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 210 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.